NasdaqGS - Nasdaq Real Time Price USD

Sanofi (SNY)

51.98

-0.53

(-1.01%)

At close: May 23 at 4:00:00 PM EDT

51.90

-0.08

(-0.15%)

After hours: May 23 at 7:44:49 PM EDT

Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Zacks yesterday

NVO

PFE

SNY
-1.01%
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the

TipRanks yesterday

SNY
-1.01%

SNYNF

VIGL
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.

PR Newswire yesterday

SNY
-1.01%

SNYNF
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push

Market analysts have called Vigil’s oral drug a "paradigm shifter" in Alzheimer’s disease treatment.

Pharmaceutical Technology yesterday

SNY
-1.01%

VIGL
European Equities Close Lower in Thursday Trading; Eurozone Business Activity Swings to Contraction

European stock markets closed lower in Thursday trading as the Stoxx Europe 600 fell 0.64%, Germany'

PREMIUM
MT Newswires yesterday

^GDAXI

DZZ

SNY
-1.01%
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi

Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be acquired by French pharmaceutical giant Sanofi.

Investopedia yesterday

SNY
-1.01%

VIGL
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.

Zacks yesterday

MRNA

PFE

SNY
-1.01%
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.

Zacks yesterday

SNY
-1.01%

VIGL
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying

Vigil Neuroscience tripled Thursday after Sanofi agreed to buy it for $470 million plus a CVR tied to its experimental Alzheimer's treatment.

Investor's Business Daily yesterday

SNY
-1.01%

SNYNF

AMGN
Sanofi gains experimental Alzheimer’s drug through Vigil buyout

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing a total deal value of $470 million.

BioPharma Dive 2 days ago

SNY
-1.01%

VIGL
Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition

Vigil Neuroscience, Inc. (NASDAQ:VIGL) on Wednesday disclosed that it entered a deal to be acquired by Sanofi (NASDAQ:SNY) for an equity value of approximately $470 million (on a fully diluted basis). Per the terms, Sanofi will pay $8.00 per share in cash to acquire Vigil. In addition, shareholders will be granted a non-tradeable contingent value right (CVR), which could provide an extra $2.00 per share in cash if VG-3927 achieves its first commercial sale within a designated timeframe. The tota

Benzinga 2 days ago

SNY
-1.01%

VIGL
Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal

Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company, for around $470 million, aiming to strengthen its research pipeline with a potential new Alzheimer’s treatment. Under the agreement, Vigil shareholders will receive $8 per share, along with the possibility of an extra $2 per share through a contingent value right […]

Insider Monkey 2 days ago

SNY
-1.01%

VIGL
Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play

Investing.com-- French pharmaceutical giant Sanofi SA (EPA:SASY) said on Wednesday it had entered an agreement to buy U.S.-listed biotech firm Vigil Neuroscience Inc (NASDAQ:VIGL), with focus chiefly on an early-stage Alzheimer’s drug being developed by the firm.

Investing.com 2 days ago

SNY
-1.01%

VIGL
Sanofi to Buy Vigil Neuroscience for About $470 Million

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer’s disease to the French pharmaceutical company’s pipeline.

The Wall Street Journal 2 days ago

VIGL

SNY
-1.01%

SNYNF
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer’s disease – - Companies expect transaction to close in third quarter of

GlobeNewswire 2 days ago

VIGL

SNY
-1.01%

SNYNF
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances Sanofi’s early-stage pi

GlobeNewswire 2 days ago

SNY
-1.01%

SNYNF
Viz.ai, Sanofi and Regeneron to link for COPD management

The partnership is poised to increase patient impact, especially for those who would benefit from enhanced care co-ordination.

Pharmaceutical Technology 2 days ago

REGN

SNY
-1.01%
Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management

Sanofi (ENXTPA:SAN) recently entered into a multi-year partnership with Viz.ai and Regeneron to develop an AI-powered solution for COPD management, reflecting its focus on innovation. Over the last month, the company’s stock increased by 1.71%, paralleling broader market trends, which have seen modest gains amid easing trade concerns and strong corporate earnings. This stock movement coincides with Sanofi's robust Q1 earnings growth and a significant share buyback completion. The company’s...

Simply Wall St. 3 days ago

SNY
-1.01%

SNYNF
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of control before randomisation.

Pharmaceutical Technology 3 days ago

REGN

SNY
-1.01%
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine

Novavax Breaks Out as FDA OKs Shot for High-Risk Groups

GuruFocus.com 4 days ago

NVAX

SNY
-1.01%

Performance Overview

Return	SNY	CAC 40 (^FCHI)
YTD	+12.55%	+4.79%
1-Year	+7.79%	-4.54%
3-Year	+8.50%	+21.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi (SNY)

Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More

Vigil Neuroscience to be acquired by Sanofi for $8.00 per share

Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push

European Equities Close Lower in Thursday Trading; Eurozone Business Activity Swings to Contraction

Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi

MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout

Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying

Sanofi gains experimental Alzheimer’s drug through Vigil buyout

Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition

Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal

Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play

Sanofi to Buy Vigil Neuroscience for About $470 Million

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Viz.ai, Sanofi and Regeneron to link for COPD management

Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management

ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care

Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine

Performance Overview